Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL IX: IDegLira vs IGlar in T2DM
NCT02773368Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2016
- Primary completion
- Sep 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 3 trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started May 2016; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02773368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02773368.